Dublin, April 03, 2023 (GLOBE NEWSWIRE) -- The "Global Autoimmune Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Autoimmune Partnering 2016 to 2023 provides the full collection of autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
- Trends in autoimmune partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Autoimmune partnering agreement structure
- Autoimmune partnering contract documents
- Top autoimmune deals by value
- Most active autoimmune dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering autoimmune deals.
The report includes coverage of the following autoimmune diseases:
Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Cronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
The report presents financial deal terms values for autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of autoimmune dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in autoimmune dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading autoimmune deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to autoimmune deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all autoimmune partnering deals by specific autoimmune target announced since 2016. The chapter is organized by specific autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all autoimmune partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in autoimmune partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of autoimmune technologies and products.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in autoimmune dealmaking
2.1. Introduction
2.2. Autoimmune partnering over the years
2.3. Autoimmune partnering by deal type
2.4. Autoimmune partnering by industry sector
2.5. Autoimmune partnering by stage of development
2.6. Autoimmune partnering by technology type
Chapter 3 -Financial deal terms for autoimmune partnering
3.1. Introduction
3.2. Disclosed financials terms for autoimmune partnering
3.3. Autoimmune partnering headline values
3.4. Autoimmune deal upfront payments
3.5. Autoimmune deal milestone payments
3.6. Autoimmune royalty rates
Chapter 4 - Leading autoimmune deals and dealmakers
4.1. Introduction
4.2. Most active in autoimmune partnering
4.3. List of most active dealmakers in autoimmune
4.4. Top autoimmune deals by value
Chapter 5 - Autoimmune contract document directory
5.1. Introduction
5.2. Autoimmune partnering deals where contract document available
Chapter 6 - Autoimmune dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by autoimmune therapeutic target
Selection of Companies Mentioned
- 3M Drug Delivery Systems
- 3SBio
- 23andMe
- Abarca
- AB Biosciences
- Abbott Laboratories
- Abbvie
- Ablynx
- Abreos Biosciences
- Abzena
- Accelerated Cure Project for MS
- Accelis Pharma
- Accord Healthcare
- Aclaris Therapeutics
- Acorda Therapeutics
- Adacyte Therapeutics
- AdAlta
- Adare Pharmaceuticals
- Adherium
- Adocia
- Aduro BioTech
- Adynxx
- Aequus Pharmaceuticals
- Aerial BioPharma
- Aerpio Therapeutics
- Aesthetic Management Partners
- Aevi Genomic Medicine
- Affibody
- Afimmune
- AGC Biologics
- AIDS Clinical Trials Group
- AiVita Biomedical
- Akaal Pharma
- Akebia Therapeutics
- Akorn
- Akouos
- Akston Biosciences
- Alana Healthcare
- Alexion Pharmaceuticals
- Alfasigma
- Alkermes
- Allakos
- Allegheny Technologies
- Allegro Ophthalmics
- Allen Institute for Brain Science
- Allergan
- Allergan (name changed from Actavis)
- Alliance for Lupus Research
- Alma Bio Therapeutics
- Almirall
- Alnylam Pharmaceuticals
- Alpine Immune Sciences
- Altair
- AltaVoice
- ALTuCELL
- Alvine Pharmaceuticals
- Alvit LCS Pharma
- Alvotech
- Alzheimer's Association
- Amarex Clinical Research
- Amegabiotech
- American College of Chest Physicians
- American Diabetes Association
- American Lung Association
- American National Multiple Sclerosis Society
- Amgen
- AmorChem
- AMPEL BioSolutions
- Andromeda Biotech
- AnGes MG
- Angiocrine Bioscience
- Anika Therapeutics
- ANI Pharmaceuticals
- Annette Funicello Research Fund for Neurological Diseases (AFRFND)
- Anokion
- Anthem Bluecross
- Anthera Pharmaceuticals
- Antidote
- Apexigen
- Aphios
- Applied Molecular Transport
- Aptar Pharma
- Aptuit
- Aralez Pharmaceuticals
- Aratana Therapeutics
- Arch Biopartners
- Arcutis Biotherapeutics
- Arena Pharmaceuticals
- argenx
- Aristea Therapeutics
- Ark Biosciences
- Array Biopharma
- Arrien Pharmaceuticals
- Asana Medical
- ASKA Pharmaceuticals
- AskAt
- Assembly Biosciences
- Astellas Pharma
- Asthma UK
- Astion Pharma
- AstraZeneca
- Atara Biotherapeutics
- Atnahs Pharma
- Atopix
- Atreca
- Aurinia Pharmaceuticals
- Auris Medical
- Australasian Gastro Intestinal Research Foundation
- Avacta
- Avalere Health
- Axela
- AXIM Biotechnologies
- Axsome Therapeutics
- Azitra
- Bachem
- Back-A-Line
- Basilea Pharmaceutica
- Bausch & Lomb
- Bausch Health Companies
- Baxalta
- Baxter International
- Bayer
- Baylor Health Care System
- Baylor Research Institute
- Bazelet
- BC Children's Hospital
- BCD Bioscience
- BDD Pharma
- Berg
- Beta-O2
- Beyond Type 1
- BGI
- Biametrics
- Bigfoot Biomedical
- Bill and Melinda Gates Foundation
- Bina Technologies
- Bio-Cancer Treatment International
- Bio-Path
- Bio-Rad Laboratories
- biOasis Technologies
- BioCad Holding
- Biocon
- Biogen
- Biohaven Pharmaceutical Holding
- BiolineRX
- Biomecite Diagnostics
- Biomedical Catalyst Fund (UK)
- BioMed X Innovation Center
- BiomX
- Bionure
- Bioprojet
- BioRap Technologies
- BioReliance
- BioSense Global
- BioStorage Technologies
- BirchBioMed
- BL&H
- Blue Cross Blue Shield Association
- BlueRock Therapeutics
- Blue Shield of California
- Boehringer Ingelheim
- Boragen
- Boston Pharmaceuticals
- Boston University School of Medicine
- Bpifrance
- BrainStorm Cell Therapeutics
- Breckenbridge Pharmaceutical
- Brickell Biotech
- Bridge Biotherapeutics
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- British Lung Foundation
- Broad Institute
- Buck Institute for Age Research
- Cadila Pharmaceuticals
- Caladrius Biosciences
- California Institute for Biomedical Research
- California Institute for Regenerative Medicine
- Calliditas Therapeutics
- Calypso Biotech
- Camargo Pharmaceutical Services
- Cambridge Clinical Laboratories
- Cambridge Enterprise
- Camino Partnership
- Cam Med
- Can-Fite BioPharma
- Canbex Therapeutics
- Canigma
- Cantargia
- Cara Therapeutics
- CareFirst BlueCross BlueShield
- Casebia Therapeutics
- Case Western Reserve University
- CEA-Leti
- Cedars-Sinai Medical Center
- Celdara Medical
- Celgene
- Celimmune
- Cell Therapy Catapult
- Celltrion
- Celmatix
- Celon Pharma
- Cel Sci
- Celsius Therapeutics
- Central Institute for Experimental Animals
- Centre for Drug Research and Development (CDRD)
- Centre Hospitalier Regional Universitaire (CHRU) de Lille
- Centre National de la Recherche Scientifique
- Centurion
- CheckPoint Immunology
- Chelexa Biosciences
- Chiesi Farmaceutici
- Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
- Children's Hospital Boston
- Chinese University of Hong Kong
- Chong Kun Dang
- Chronos Therapeutics
- Chugai Pharmaceutical
- CHU Sainte-Justine
- Cicero Diagnostics
- Cigna Healthcare
- Cipher Pharmaceuticals
- Cipla
- Circassia
- Clal Biotech
- Clarify Medical
- Clearside Biomedical
- Clene Nanomedicine
- Cleveland Clinic
- Clinigen
- CMS Medical
- Cochin Hospital
- Coherus Biosciences
- Columbia University
- Columbia University Medical Center
- Complix
- Convelo Therapeutics
- Cook Biotech
- COPD Foundation
- Corbin Therapeutics
- Corbus Pharmaceuticals
- CORD:USE
- Cornell University
- CorTechs Labs
- COUR Pharmaceutical
- Covalent Data
- CRISPR Therapeutics
- Crohn's and Colitis Foundation of America
- CR Pharma
- CRS Bio
- CrystalGenomics
- CSL Behring
- Cue Biopharma
- Cumberland Pharmaceuticals
- Curable
- Curant Health
- Cureveda
- CyDex
- Cynata Therapeutics
- Cyxone
- Daewoong Pharmaceutical
- Daiichi Sankyo
- Dalton Pharma Services
- Dartmouth College
- DBV Technologies
- Debiotech
- DecImmune Therapeutics
- Defymed
- Delphi Genetics
- Denali Therapeutics
- DendroCyte
- Dermavant Sciences
- Dermira
- Diabeloop
- Diamyd Medical
- Diomics
- Diplomat
- Diversigen
- Domainex
- Dr. Falk Pharma
- Dr. Reddy's Laboratories
- Dragonfly Therapeutics
- DreaMed Diabetes
- DS Biopharma
- Duke-NUS Graduate Medical School Singapore
- Duke Clinical Research Institute (DCRI)
- EA Pharma
- Eddingpharm
- EGeen
- Eisai
- Eisai Inc
- Eleven Biotherapeutics
- Eli Lilly
- Elite Pharmaceuticals
- ElsaLys Biotech
- EMD Serono
- Emory University
- EMS
- Enable Biosciences
- Encore Dermatology
- Endo International
- enGene
- Engitix
- Entera Health
- Enteris Biopharma
- Enterome Bioscience
- Entos Pharmaceuticals
- EOFlow
- Epicore Biosystems
- EPI Health
- Epirus Biopharmaceuticals
- Epivax
- Equillium
- Erasmus University Medical Center
- European Bioinformatics Institute
- European Union
- European Union Regional Development Fund
- Everest Medicines
- Evestra
- Evidation Health
- Evotec
- Ewopharma
- Exagen Diagnostics
- Exco InTouch
- ExeGi Pharma
- Exicure
- ExScientia
- EyePoint Pharmaceuticals
- Fast Forward
- Fate Therapeutics
- Federal Ministry of Education and Research (BMBF)
- Federal Ministry of Health (Germany)
- Feinstein Institute for Medical Research
- Ferring Pharmaceuticals
- Fibrocor Therapeutics
- Finch Therapeutics
- Fission Labs LATAM
- Flemish agency for Innovation by Science and Technology
- Fluidigm
- Food and Drug Administration (FDA)
- Foresee Pharmaceuticals
- Forward Pharma
- Fougera Pharmaceuticals
- Foundation for Celiac Disease Outcome Measures
- Foundation for Diabetes Research
- French National Institute for Agricultural Research
- Fresenius Kabi Pharmaceuticals
- FSD Pharma
- Fudan University
- Fujifilm Diosynth Biotechnologies
- Fujifilm Kyowa Kirin Biologics
- Fuji Pharma
- Galapagos
- Galderma
- Galecto Biotech
- Gebro Pharma
- GE Healthcare
- Genentech
- Generex Biotechnology
- Genetic Analysis
- GeNeuro
- Genexine
- Genmab
- Genomics
- Genprex
- Genten Therapeutics
- Genzyme
- Georgetown University
- George Washington University
- Georgia State University
- Gilead Sciences
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Glialogix
- Global Centers for Therapeutic Innovation
For more information about this report visit https://www.researchandmarkets.com/r/tr0yfr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
